Long Term Follow-up of the TREOCAPA Study (TREOCAPA-LT)
NCT ID: NCT06064825
Last Updated: 2025-04-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
500 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-12-12
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The ductus arteriosus (DA) is a large channel connecting the main pulmonary trunk with the descending aorta. In extremely preterm infants, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. PDA treatment with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Early treatment of PDA with paracetamol (acetaminophen ) has been proposed as an alternative to COX inhibitors. The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age. As long-term follow-up was not planned by the TREOCAPA protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform (https://recap-preterm.eu/), to follow-up the patients enrolled in the TREOCAPA trial using a parent-report questionnaire at 2 years of corrected age.
The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA phase III trial.
The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA phase III trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications
NCT03289390
Patent Ductus Arteriosus
COMPLETED
Timing of Surgical PDA Ligation and Neonatal Outcomes
NCT04126512
Patent Ductus Arteriosus
Patent Ductus Arteriosus - Delayed Closure
Patent Ductus Arteriosus After Premature Birth
COMPLETED
Normal Hemostasis Values in Premature Infants
NCT07349251
Premature Infant, Hemostasis
RECRUITING
Betamethasone and Closure of Ductus Arteriosus
NCT05987202
Persistent Ductus Arteriosus
RECRUITING
Noninvasive Hemodynamics Assessment of Preterms With Successful Medical Closure of PDA
NCT06606015
Patent Ductus Arteriosus in Preterm Infants
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The ductus arteriosus (DA) is a large channel found normally in all mammalian foetuses, connecting the main pulmonary trunk with the left-sided descending aorta. During fetal life, it diverts most of the combined ventricular output away from the lungs toward the placenta. In full-term newborns, the DA is functionally open in all newborns and its constriction and closure, within 24 to 48 hours after delivery, are part of the normal process of postnatal adaptation. In extremely preterm infants, ie, those born before 29 weeks of gestation, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. Inhibition of prostaglandin synthesis, through inhibition of the cyclo-oxygenase (COX) enzymes, results in ductal constriction. However, treatments with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Prophylactic use of indomethacin or ibuprofen has been shown to reduce subsequent development of PDA but not to reduce mortality or morbidity. Further, investigations of early cardiac ultrasound-targeted treatment of a large PDA using indomethacin and ibuprofen do not show efficacy on primary outcomes of neonatal death or morbidity. Although this evidence base shows that prophylactic treatment by indomethacin or ibuprofen cannot be recommended, evidence from observational studies suggests that early (during the first 3 days of life) conservative treatment should not be recommended either. Two observational studies indicated that ignoring a PDA during the first days of life is associated with increase in mortality or morbidity. Our interpretation of these results is that screening echocardiography of large ductus arteriosus and early targeted treatment using echocardiography reduce pulmonary haemorrhage, but that the use of drugs with severe adverse effects may cancel expected beneficial effects on the occurrence of death or morbidity.
The use of a medication with an effect on PDA and that has fewer adverse effects is therefore desirable. Early treatment of PDA with paracetamol (acetaminophen) has been proposed as an alternative to COX inhibitors. According to a recent meta-analysis, use of paracetamol has a comparable effectiveness to close a PDA, and fewer harmful effects. However, only few extremely preterm infants were included in this meta-analysis. Therefore, efficacy and safety of paracetamol for PDA treatment in this population required further studies.
The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age.12 The trial has been powered to identify an absolute difference of 10% in the primary outcome, survival without severe neonatal morbidity (defined as any of: bronchopulmonary dysplasia grade 3 according to National Institute of Health criteria, necrotising enterocolitis stage 2 or 3 using Bell's criteria, intraventricular haemorrhage grade III or IV using the classification of Papile et al, or any evidence of cystic periventricular leukomalacia), corresponding to an increase from 50% to 60% in the rate between groups at hospital discharge. It aims to recruit 398 infants born at 27-28 weeks of gestation, and 396 infants born at 23-26 weeks of gestation. The first patients were recruited in October 2020 and the recruitment period is anticipated to last until April 2024 at the latest.
The TREOCAPA phase III trial is ambitious and innovative in its scope, including more than 40 hospitals in 16 countries. However, long-term follow-up was not included in the TREOCAPA protocol. The follow-up of infants enrolled in clinical trials enables to measure the long-term effectiveness and safety of interventions performed in the neonatal period. In particular for exposition to paracetamol in the neonatal period, data from randomized studies are very limited, while long-term adverse effects of paracetamol, including notably behavioral problems, have been raised. There is hence a need to understand longer term outcomes for the infants enrolled in this study, as these longer-term endpoints correspond to important patient-valued outcomes and are critical to determining the comparative effectiveness of interventions. The working hypothesis, if the intervention has a positive impact on short-term endpoints, is that longer term outcomes will be better in the intervention group, reflecting reduced morbidity at discharge home from the neonatal hospitalisation.
As long-term follow-up was not planned by the TREOCAPA phase III protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform to follow-up patients enrolled in the TREOCAPA cohort at 2 years of corrected age. This platform federates 23 European longitudinal observational cohorts of children born very preterm. The platform includes expertise, tools and infrastructure to follow patients enrolled in trials. By integrating trial follow-up in this platform, it is also possible to compare patients enrolled in the TREOCAPA trial with those from population-based samples, allowing assessment of transportability of trial results.
Follow-up at 2 years of age is recommended as the focus for the first phase of long-term outcome monitoring and has become the de facto age which is used in many published and ongoing clinical trials. Furthermore, many hospital services provide follow-up for their patients until at least 2 years of age, and research contact with the families at this point provides an opportunity to maintain contact and demonstrate to patients the ongoing importance of their involvement in the study.
The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA trial.
Secondary hypotheses are that, among children treated with paracetamol/acetaminophen during the first 5 days of life:
1. There will be reduced moderate or severe neurodevelopmental impairment, defined as the presence of at least one of the following: PARCA-R non-verbal cognitive score less than two standard deviations below the mean (score \<70) moderate-severe motor impairment, unilateral or bilateral deafness or blindness.
2. There will be reduced need for secondary hospitalisations following the initial neonatal hospitalisation.
3. There will be reduced long term health care utilisation costs associated with extremely preterm birth.
Secondary hypotheses also relate to the use of the RECAP Preterm platform of observational VPT cohorts in this study. These are that:
1. As a trial population, the children born VPT included in the TREOCAPA-LT study will differ from those included in population-based observational cohorts in their perinatal characteristics and possibly in their health and developmental outcomes.
2. That these differences in population characteristics can affect the transportability of the trial results to other populations of VPT infants.
The use of a medication with an effect on PDA and that has fewer adverse effects is therefore desirable. Early treatment of PDA with paracetamol (acetaminophen) has been proposed as an alternative to COX inhibitors. According to a recent meta-analysis, use of paracetamol has a comparable effectiveness to close a PDA, and fewer harmful effects. However, only few extremely preterm infants were included in this meta-analysis. Therefore, efficacy and safety of paracetamol for PDA treatment in this population required further studies.
The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age.12 The trial has been powered to identify an absolute difference of 10% in the primary outcome, survival without severe neonatal morbidity (defined as any of: bronchopulmonary dysplasia grade 3 according to National Institute of Health criteria, necrotising enterocolitis stage 2 or 3 using Bell's criteria, intraventricular haemorrhage grade III or IV using the classification of Papile et al, or any evidence of cystic periventricular leukomalacia), corresponding to an increase from 50% to 60% in the rate between groups at hospital discharge. It aims to recruit 398 infants born at 27-28 weeks of gestation, and 396 infants born at 23-26 weeks of gestation. The first patients were recruited in October 2020 and the recruitment period is anticipated to last until April 2024 at the latest.
The TREOCAPA phase III trial is ambitious and innovative in its scope, including more than 40 hospitals in 16 countries. However, long-term follow-up was not included in the TREOCAPA protocol. The follow-up of infants enrolled in clinical trials enables to measure the long-term effectiveness and safety of interventions performed in the neonatal period. In particular for exposition to paracetamol in the neonatal period, data from randomized studies are very limited, while long-term adverse effects of paracetamol, including notably behavioral problems, have been raised. There is hence a need to understand longer term outcomes for the infants enrolled in this study, as these longer-term endpoints correspond to important patient-valued outcomes and are critical to determining the comparative effectiveness of interventions. The working hypothesis, if the intervention has a positive impact on short-term endpoints, is that longer term outcomes will be better in the intervention group, reflecting reduced morbidity at discharge home from the neonatal hospitalisation.
As long-term follow-up was not planned by the TREOCAPA phase III protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform to follow-up patients enrolled in the TREOCAPA cohort at 2 years of corrected age. This platform federates 23 European longitudinal observational cohorts of children born very preterm. The platform includes expertise, tools and infrastructure to follow patients enrolled in trials. By integrating trial follow-up in this platform, it is also possible to compare patients enrolled in the TREOCAPA trial with those from population-based samples, allowing assessment of transportability of trial results.
Follow-up at 2 years of age is recommended as the focus for the first phase of long-term outcome monitoring and has become the de facto age which is used in many published and ongoing clinical trials. Furthermore, many hospital services provide follow-up for their patients until at least 2 years of age, and research contact with the families at this point provides an opportunity to maintain contact and demonstrate to patients the ongoing importance of their involvement in the study.
The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA trial.
Secondary hypotheses are that, among children treated with paracetamol/acetaminophen during the first 5 days of life:
1. There will be reduced moderate or severe neurodevelopmental impairment, defined as the presence of at least one of the following: PARCA-R non-verbal cognitive score less than two standard deviations below the mean (score \<70) moderate-severe motor impairment, unilateral or bilateral deafness or blindness.
2. There will be reduced need for secondary hospitalisations following the initial neonatal hospitalisation.
3. There will be reduced long term health care utilisation costs associated with extremely preterm birth.
Secondary hypotheses also relate to the use of the RECAP Preterm platform of observational VPT cohorts in this study. These are that:
1. As a trial population, the children born VPT included in the TREOCAPA-LT study will differ from those included in population-based observational cohorts in their perinatal characteristics and possibly in their health and developmental outcomes.
2. That these differences in population characteristics can affect the transportability of the trial results to other populations of VPT infants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients received the investigational medicinal product acetaminophen in their first 5 days of life
This group of patients received the investigational product in their first 5 days of life during the Treocapa trial
2 year follow-up of neurodevelopment using a parental questionnaire
Intervention Type
OTHER
A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
patients received the placebo (NaCl) in their first 5 days of life
This group of patients received the placebo in their first 5 days of life during the Treocapa trial
2 year follow-up of neurodevelopment using a parental questionnaire
Intervention Type
OTHER
A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2 year follow-up of neurodevelopment using a parental questionnaire
A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* were included in the TREOCAPA phase III RCT in participating centres
* are aged between 23.5 and 27.5 months corrected age during the study period
* are aged between 23.5 and 27.5 months corrected age during the study period
Exclusion Criteria
* if the local investigator does not have up-to-date contact information allowing contact with parents
* if the child's vital status cannot be ascertained
* if the child is nearing the end of his life or experiencing a severe medical event as assessed by the local investigator
* if the child has become subject to a legal protection measure preventing their ongoing participation in clinical research
* if either parent or guardian opts out of participating
* language barrier
* if the child's vital status cannot be ascertained
* if the child is nearing the end of his life or experiencing a severe medical event as assessed by the local investigator
* if the child has become subject to a legal protection measure preventing their ongoing participation in clinical research
* if either parent or guardian opts out of participating
* language barrier
Minimum Eligible Age
23 Months
Maximum Eligible Age
27 Months
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Zeitlin
Role: STUDY_DIRECTOR
Institut National de la Santé Et de la Recherche Médicale, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Angers
Angers, , France
Site Status
RECRUITING
Hôpital Femme Mère Enfant
Bron, , France
Site Status
RECRUITING
CHU de Montpellier
Montpellier, , France
Site Status
RECRUITING
CHU de Nantes
Nantes, , France
Site Status
RECRUITING
Cochin - APHP
Paris, , France
Site Status
RECRUITING
Hopital Robert Debré
Paris, , France
Site Status
RECRUITING
CHU de Strasbourg
Strasbourg, , France
Site Status
RECRUITING
CHU de Tours
Tours, , France
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marion Plourde
Role: primary
Kim An Nguyen
Role: primary
Gilles Cambonie
Role: primary
Cyril Flamant
Role: primary
Juliana Patkai
Role: primary
Valérie Biran
Role: primary
Pierre Kuhn
Role: primary
Antoine Bouissou
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000 Sep 7;343(10):728-30. doi: 10.1056/NEJM200009073431009. No abstract available.
Reference Type
BACKGROUND
Hamrick SEG, Sallmon H, Rose AT, Porras D, Shelton EL, Reese J, Hansmann G. Patent Ductus Arteriosus of the Preterm Infant. Pediatrics. 2020 Nov;146(5):e20201209. doi: 10.1542/peds.2020-1209.
Reference Type
BACKGROUND
Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588. doi: 10.1002/14651858.CD013588.pub2.
Reference Type
BACKGROUND
Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010 Jul 7;2010(7):CD000174. doi: 10.1002/14651858.CD000174.pub2.
Reference Type
BACKGROUND
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2018 Sep 28;9(9):CD003481. doi: 10.1002/14651858.CD003481.pub7.
Reference Type
BACKGROUND
Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F99-F104. doi: 10.1136/archdischild-2013-304695. Epub 2013 Dec 6.
Reference Type
BACKGROUND
Roze JC, Cambonie G, Le Thuaut A, Debillon T, Ligi I, Gascoin G, Patkai J, Beuchee A, Favrais G, Flamant C, Durrmeyer X, Clyman R. Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. J Pediatr. 2021 Jun;233:33-42.e2. doi: 10.1016/j.jpeds.2020.12.008. Epub 2020 Dec 9.
Reference Type
BACKGROUND
Liebowitz M, Clyman RI. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes. J Pediatr. 2017 Aug;187:119-126.e1. doi: 10.1016/j.jpeds.2017.03.021. Epub 2017 Apr 7.
Reference Type
BACKGROUND
Roze JC, Cambonie G, Marchand-Martin L, Gournay V, Durrmeyer X, Durox M, Storme L, Porcher R, Ancel PY; Hemodynamic EPIPAGE 2 Study Group. Association Between Early Screening for Patent Ductus Arteriosus and In-Hospital Mortality Among Extremely Preterm Infants. JAMA. 2015 Jun 23-30;313(24):2441-8. doi: 10.1001/jama.2015.6734.
Reference Type
BACKGROUND
Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J, Nelson K, Wickremasinghe A, Dong L, Hassinger DC, Aucott SW, Hayashi M, Heuchan AM, Carey WA, Derrick M, Fernandez E, Sankar M, Leone T, Perez J, Serize A; PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr. 2019 Feb;205:41-48.e6. doi: 10.1016/j.jpeds.2018.09.012. Epub 2018 Oct 16.
Reference Type
BACKGROUND
Jasani B, Mitra S, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2022 Dec 15;12(12):CD010061. doi: 10.1002/14651858.CD010061.pub5.
Reference Type
BACKGROUND
Marlow N, Doyle LW, Anderson P, Johnson S, Bhatt-Mehta V, Natalucci G, Darlow BA, Davis JM, Turner MA; International Neonatal Consortium (INC). Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants. Pediatr Res. 2019 Nov;86(5):567-572. doi: 10.1038/s41390-019-0526-1. Epub 2019 Aug 9.
Reference Type
BACKGROUND
Masarwa R, Levine H, Gorelik E, Reif S, Perlman A, Matok I. Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies. Am J Epidemiol. 2018 Aug 1;187(8):1817-1827. doi: 10.1093/aje/kwy086.
Reference Type
BACKGROUND
Baker BH, Lugo-Candelas C, Wu H, Laue HE, Boivin A, Gillet V, Aw N, Rahman T, Lepage JF, Whittingstall K, Bellenger JP, Posner J, Takser L, Baccarelli AA. Association of Prenatal Acetaminophen Exposure Measured in Meconium With Risk of Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity. JAMA Pediatr. 2020 Nov 1;174(11):1073-1081. doi: 10.1001/jamapediatrics.2020.3080.
Reference Type
BACKGROUND
Inoue K, Ritz B, Ernst A, Tseng WL, Yuan Y, Meng Q, Ramlau-Hansen CH, Strandberg-Larsen K, Arah OA, Obel C, Li J, Olsen J, Liew Z. Behavioral Problems at Age 11 Years After Prenatal and Postnatal Exposure to Acetaminophen: Parent-Reported and Self-Reported Outcomes. Am J Epidemiol. 2021 Jun 1;190(6):1009-1020. doi: 10.1093/aje/kwaa257.
Reference Type
BACKGROUND
Johnson S, Bountziouka V, Brocklehurst P, Linsell L, Marlow N, Wolke D, Manktelow BN. Standardisation of the Parent Report of Children's Abilities-Revised (PARCA-R): a norm-referenced assessment of cognitive and language development at age 2 years. Lancet Child Adolesc Health. 2019 Oct;3(10):705-712. doi: 10.1016/S2352-4642(19)30189-0. Epub 2019 Aug 8.
Reference Type
BACKGROUND
Draper ES, Zeitlin J, Manktelow BN, Piedvache A, Cuttini M, Edstedt Bonamy AK, Maier R, Koopman-Esseboom C, Gadzinowski J, Boerch K, van Reempts P, Varendi H, Johnson SJ; EPICE group. EPICE cohort: two-year neurodevelopmental outcomes after very preterm birth. Arch Dis Child Fetal Neonatal Ed. 2020 Jul;105(4):350-356. doi: 10.1136/archdischild-2019-317418. Epub 2019 Nov 5.
Reference Type
BACKGROUND
Seppanen AV, Bodeau-Livinec F, Boyle EM, Edstedt-Bonamy AK, Cuttini M, Toome L, Maier RF, Cloet E, Koopman-Esseboom C, Pedersen P, Gadzinowski J, Barros H, Zeitlin J; Effective Perinatal Intensive Care in Europe (EPICE) research group. Specialist health care services use in a European cohort of infants born very preterm. Dev Med Child Neurol. 2019 Jul;61(7):832-839. doi: 10.1111/dmcn.14112. Epub 2018 Dec 3.
Reference Type
BACKGROUND
Seppanen AV, Draper ES, Petrou S, Barros H, Aubert AM, Andronis L, Kim SW, Maier RF, Pedersen P, Gadzinowski J, Lebeer J, Aden U, Toome L, van Heijst A, Cuttini M, Zeitlin J; SHIPS Research Group. High Healthcare Use at Age 5 Years in a European Cohort of Children Born Very Preterm. J Pediatr. 2022 Apr;243:69-77.e9. doi: 10.1016/j.jpeds.2021.12.006. Epub 2021 Dec 16.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01418-37
Identifier Type: REGISTRY
Identifier Source: secondary_id
C23-31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants
NCT03982342
TERMINATED
NA
Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates
NCT03022253
COMPLETED
PHASE3
Prophylactic IV Paracetamol in Extremely Premature Infants
NCT07067177
ENROLLING_BY_INVITATION
PHASE2/PHASE3
PDA Post NICU Discharge
NCT02750228
COMPLETED
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
NCT03782610
ACTIVE_NOT_RECRUITING
Alternative Paracetamol Treatments for the Neonate With a hsPDA
NCT03604796
UNKNOWN
PHASE2/PHASE3
Tracheal Occlusion To Accelerate Lung Growth (TOTAL) Trial for Severe Pulmonary Hypoplasia
NCT01240057
COMPLETED
PHASE2/PHASE3
The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants
NCT02602054
UNKNOWN
PHASE2
Study of Thoracic Ultrasound As a Response to the Closure of Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants
NCT06627374
RECRUITING
New Management Strategy of PDA for VLBW Preterm Infants
NCT00239512
TERMINATED
NA
Comparison of Infusion Paracetamol Protocols in PDA
NCT04469413
COMPLETED
Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
NCT06950164
ACTIVE_NOT_RECRUITING
Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants
NCT00004840
COMPLETED
NA
N-Terminal Pro-B-Type Natriuretic Peptide and Troponin Levels as Markers of Hemodynamic Stability in Very Low Birth Weight Infants During the First Days of Life
NCT00425581
WITHDRAWN
Study of the Effect of Hydrocortisone Administered for the Prevention of Pulmonary Bronchodysplasia (PREMILOC Trial) on the Determinants of Systemic Blood Pressure in Children (PREMILOCAP)
NCT05451264
RECRUITING
NA
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
RECRUITING
NA
The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants
NCT00500305
COMPLETED
NA
Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness
NCT06499363
RECRUITING
Early Treatment Versus Expectative Management of PDA in Preterm Infants
NCT02884219
COMPLETED
NA
Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies
NCT00725647
COMPLETED
Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants
NCT00162903
COMPLETED
Early Treatment Versus Expectant Management of PDA in Preterm Infants
NCT03860428
COMPLETED
NA
International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial
NCT02910609
UNKNOWN
Simultaneous Study of the Serum Tryptase Level of the Mother and the Child During Childbirth (TryPla)
NCT04441463
UNKNOWN
NA
Management of the PDA Trial
NCT03456336
ACTIVE_NOT_RECRUITING
PHASE3